Telix Pharmaceuticals Limited (TLX)
| Market Cap | 3.22B -41.8% |
| Revenue (ttm) | 803.79M +55.6% |
| Net Income | -7.13M |
| EPS | -0.02 |
| Shares Out | 338.78M |
| PE Ratio | n/a |
| Forward PE | 479.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 258,615 |
| Open | 9.66 |
| Previous Close | 10.27 |
| Day's Range | 9.46 - 9.68 |
| 52-Week Range | 6.28 - 18.49 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 29.99 (+216.68%) |
| Earnings Date | Aug 19, 2026 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $29.99, which is an increase of 216.68% from the latest price.
News
Telix Pharmaceuticals Transcript: AGM 2026
AGM highlighted strong revenue growth, global expansion, and a robust late-stage pipeline. Three new U.S.-based directors were elected, and all resolutions passed. Profits will be reinvested into R&D rather than paid as dividends.
Telix Pharmaceuticals Slides: FY 2026
Telix Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 20, 2026.
Telix Pharmaceuticals Transcript: AGM 2026
AGM highlighted strong revenue growth, global expansion, and a robust late-stage pipeline. All board and remuneration proposals passed, with new U.S.-based directors joining to support international growth. Profits will be reinvested into R&D rather than paid as dividends.
Telix Pharmaceuticals Slides: FY 2026
Telix Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 20, 2026.
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the IPAX-2 study1 of TLX101-Tx (¹³¹I-iodofal...
EDAP Explores Collaboration with Telix Pharmaceuticals on Prostate Cancer Treatments
EDAP Explores Collaboration with Telix Pharmaceuticals on Prostate Cancer Treatments
Telix, EDAP And Profound Partner To Explore PSMA-PET Imaging In Prostate Cancer Treatment
(RTTNews) - Telix Pharmaceuticals Limited (TLX) has entered into new collaborations to study how PSMA-PET imaging may support emerging, minimally invasive prostate cancer treatment approaches.
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pur...
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
MELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the publication of a new independent analysis of ...
Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Thursday presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx in treating metast...
TLX101-Px (Pixlumi®) MAA Accepted in Europe
MELBOURNE, Australia and INDIANAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the marketing authorization application (MAA...
Telix Pharmaceuticals Transcript: Status update
A next-generation radioligand therapy portfolio is advancing with TLX597-Tx showing low off-target toxicity and high tumor uptake, supporting dose intensification and adaptive dosing in prostate cancer. Early clinical data indicate favorable safety and efficacy, with ongoing trials targeting both advanced and earlier disease stages.
Telix Pharmaceuticals Slides: Status update
Telix Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 29, 2026.
Telix Pharmaceuticals Transcript: Status update
A next-generation radioligand therapy portfolio is advancing with TLX597-Tx showing low off-target toxicity and high tumor uptake, supporting dose intensification and adaptive dosing in prostate cancer. Early clinical data indicate favorable safety and efficacy, with ongoing trials targeting both advanced and earlier disease stages.
Telix Pharmaceuticals Slides: Status update
Telix Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 29, 2026.
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
MELBOURNE, Australia and INDIANAPOLIS, April 30, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces dosimetry results from the randomized Phase 2 O...
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an educational webinar exploring the evolution of PSM...
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the Pros...
Telix Pharma Doses First Patient In Phase 3 IPAX BrIGHT Trial Of TLX101-Tx; Prices $600 Mln Bonds
(RTTNews) - Telix Pharmaceuticals Ltd (TLX, TLZ.AX), a commercial-stage biopharmaceutical company, announced on Wednesday that it has dosed the first patient in the pivotal Phase 3 IPAX BrIGHT trial e...
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX1...
Fundies feast on Telix Pharmaceuticals block amid $US550m convertible
The bock trade, expected to be finalised overnight, is part of a so-called delta hedging placement usually seen around convertible bonds.
Telix and Regeneron Announce Strategic Radiopharma Collaboration
MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (NASDAQ...
FDA Accepts NDA for TLX101-Px (Pixclara®)
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Adm...
Telix Strengthens Board with Additional Director Appointments
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) app...
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational perf...